Voluntary announcement - phase iii clinical trial of SYS6043 for the first-line treatment of unresectable recurrent or metastatic triple-negative breast cancer officially initiated in china
Filed with HKEX · Stock code 1093 ·
6ix is reading this filing.
View original source (HKEXnews)CSPC Pharmaceutical Group Limited on 6ix
Earlier from CSPC Pharmaceutical
- Voluntary announcement - phase ii clinical trial of SYH2066 for the treatment of respiratory syncytial virus infection officially initiated in china
- Voluntary announcement - phase i clinical trial of SYH2083 eye drops for the treatment of dry eye disease officially initiated in china
- Voluntary announcement - grant of awarded shares pursuant to the 2026 share award scheme
- Voluntary announcement - grant of awarded shares pursuant to the 2018 share award scheme
- Voluntary announcement - SYS6088 injection (a tri-specific antibody) obtains clinical trial approval in China
Later from CSPC Pharmaceutical
All CSPC Pharmaceutical news releasesFollow CSPC Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Pharmaceutical